Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.77 |
| ▸ | CTSL | P07711 | 4/20 | 0.72 |
| ▸ | CTSS | P25774 | 3/20 | 0.72 |
| ▸ | CTSB | P07858 | 2/20 | 0.72 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.62 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25282894 | 1.00 | CTSK (0.77) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL7163191 | 0.97 | CTSK (0.73) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL7338471 | 0.90 | CTSK (0.86) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL13746427 | 0.89 | CTSK (0.81) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL29955485 | 0.89 | CTSK (0.81) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL8584231 | 0.88 | CTSK (0.64) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL1175268 | 0.88 | CTSK (0.79) | CTSKCTSLCTSSCTSB | |
| SCHEMBL13888706 | 0.88 | CTSK (0.79) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6945614 | 0.88 | CTSK (0.79) | CTSKCTSLCTSSCTSB | |
| SCHEMBL4679435 | 0.88 | CTSK (0.60) | CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004058238-A1 | USE OF CATHEPSIN K INHIBITORS FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2004-07-15 | — | — | WO | claimed |
| US-12060333-B2 | Aminocarbamoyl compounds for the treatment of viral infections | HOFFMANN-LA ROCHE INC. (US) | 2024-08-13 | — | — | US | disclosed |
| CN-116438160-A | Carbamoyl compounds for the treatment of viral infections | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4204393-A1 | AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022043374-A1 | AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-03-03 | — | — | WO | disclosed |
| US-20110059018-A1 | COVALENTLY BINDING IMAGING PROBES | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| US-6586466-B2 | Enzyme inhibitor for use in the treatment of bone, oral, arthritic, paget's and hypercalcemic diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-6562842-B2 | Osteoporosis, oral diseases | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | disclosed |
| US-20020173469-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | disclosed |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1079821-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-1068304-A1 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6057362-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-5998470-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999059570-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999053039-A1 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-21 | — | — | WO | disclosed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| CN-1177293-A | Method for inhibiting cathepsin K | SMITHKLINE BEECHAM CORP (US) | 1998-03-25 | — | — | CN | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059018-A1 | COVALENTLY BINDING IMAGING PROBES | CTSV, CTSL, CTSE | CTSK 20/4885CTSL 2/4885CTSS 9/4885 |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | PEPD, PREP, CPN1 | CTSK 64/4885CTSL 22/4885CTSS 4/4885 |
| US-12060333-B2 | Aminocarbamoyl compounds for the treatment of viral infections | SARS1, BCAT1, SLC1A5 | CTSK 2290/4885CTSL 112/4885CTSS 1275/4885 |
| US-20020173469-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | CTSK 1/4885CTSL 14/4885CTSS 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.